This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Not stated. The authors identified a multi-centred placebo controlled trial, a review (likely to be systematic) and a largescale meta-analysis of SSRIs versus TCAs.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
For initial treatment completion rates the results of 62 SSRI versus TCA trials reported by Anderson and Tomenson (1995) were used. Three other studies were also used. The AHCPR guidelines referred to in this study reviewed 13 studies involving patients being switched from TCAs to non-TCAs.
Methods of combining primary studies
Data pooling was used for initial treatment completion rates. The number of completers was divided by the number entered into the trials. Meta-analysis was also used in at least one trial used by the authors.
Investigation of differences between primary studies
Results of the review
The initial success rate for imipramine was 46% and 58% for paroxetine. Alternative initial success rates were given for 3 scenarios (using assumptions SR2 and LT2 -see estimates below): IS1 = paroxetine (65.6%) and imipramine (38.4%), which is the break-even rate (or equal cost-effectiveness); IS2 = paroxetine (63.9%) and imipramine (55.7%); IS3 = SRI (69.2%) and TCA (66.6%). TABLE C
Methods used to derive estimates of effectiveness
Estimates of effectiveness under three scenarios for success rate of switched therapies and treatment duration were derived from authors' assumptions, by reference to data findings in the literature (see above) and AHCPR guidelines.
Estimates of effectiveness and key assumptions
The success rate of switched therapies was estimated for three scenarios (SR): SR1, 28% for paroxetine to imipramine switch and 35% for imipramine to paroxetine switch; SR2, 35% for paroxetine to imipramine switch and 44% for imipramine to paroxetine switch; SR3, 41% for paroxetine to imipramine switch and 52% for imipramine to paroxetine switch.
Values were calculated on three assumptions for drop-outs: 60% of average, 75% of average and 90% of average. The assumptions thus created were all within the Agency for Health Care Policy and Research (AHCPR) guidelines for TCA to non-TCA switches (30-60%). These assumptions were more consistent with AHCPR guidelines.
NHS Economic Evaluation

Measure of benefits used in the economic analysis
Benefits were expressed in terms of successfully treated patients.
Direct costs
Discount rates of 2, 5 and 10% were applied to costs in the sensitivity analysis of the study. Costings included medication (US wholesale prices), treatment delivery and GP visits. The costing perspective was unclear.
Statistical analysis of costs
Not performed.
Currency
UK pounds sterling (), mainly converted from US dollars at a rate of 1 = $1.60.
Sensitivity analysis
One-way sensitivity analysis varied different study assumptions including drug costs, dosages, treatment delivery and failure costs, relapse probability, retreatment success probability and GP maintenance visits. No prices were stated.
Estimated benefits used in the economic analysis
Benefits were expressed in terms of reduced costs per successfully treated patient (see synthesis of costs and benefits below).
Cost results
Total intervention costs were not reported.
Synthesis of costs and benefits
Costs per successfully treated patient under three scenarios were:
IS1, 897 (paroxetine) and 897 (imipramine); IS2, 836 (paroxetine) and 696 (imipramine); IS3, 765 (paroxetine) and 577 (imipramine).
These results were based on the authors' best estimates of success after switched treatment and duration of treatment. 
